Researchers Compared Adjunctive Antipsychotics for Depression
A 2026 meta-analysis evaluated five FDA-approved medications used to treat major depressive disorder.
Updated on Oct. 7, 2026 in Mental Health
Live Poll
Do you prioritize a medication's effectiveness over its potential for side effects when choosing treatment?
In 2026, researchers published a network meta-analysis of five FDA-approved adjunctive antipsychotics used for major depressive disorder. The study utilized data from randomized controlled trials to evaluate efficacy and safety outcomes.
Why it matters
Understanding the comparative efficacy and side-effect profiles of these medications is essential for clinicians optimizing treatment plans for patients with major depressive disorder. This analysis provides a standardized comparison of outcomes against placebo to help differentiate the performance of commonly prescribed adjunctive options.
The analysis compared five adjunctive antipsychotics, utilizing 95% confidence intervals to measure effect sizes against a 7% weight gain threshold. The study focused on clinical outcomes including response and remission rates.
The players
Advances in Therapy
This peer-reviewed medical journal publishes clinical research and outcomes regarding various therapeutic interventions.
U.S. Food and Drug Administration
The federal regulatory body is responsible for approving medications and oversight of drug safety protocols in the United States.
The details
Researchers performed a network meta-analysis by pooling randomized controlled trials referenced in individual drug product labels. The study found that lumateperone demonstrated a larger effect size than quetiapine extended-release, aripiprazole, brexpiprazole, and cariprazine, while showing a distinct safety profile regarding weight gain.
Timeline
The meta-analysis was published in Advances in Therapy in 2026.
The Big Picture
This analysis updates findings relative to the FDA-approved drug labeling requirements, which define the regulatory standards for clinical trial reporting. By synthesizing this data, researchers provide a new evidence-based hierarchy for comparing treatment options that were previously analyzed only against placebos.
Patients may see changes in how providers select adjunctive therapies based on the reported differences in efficacy and sedation. Understanding these profiles can assist individuals in discussing medication options and potential side effects with their healthcare team.
The takeaway
This analysis underscores the importance of evaluating medication choices through comparative clinical data rather than relying on individual trial results. Patients are encouraged to discuss these findings with their physicians to determine the most appropriate treatment path for their specific needs.
Further reading
For more on treatment trends, see Mental Health.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you prioritize a medication's effectiveness over its potential for side effects when choosing treatment?
